top of page

If you are unable to access any of our publications, please email Daniel Wetterskog to obtain a copy.

Accumulation of copy number alterations and clinical progression across advanced prostate cancer

Grist E, et al. Genome Medicine. 2022

https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01080-4

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

Orlando F, et al. NAR Cancer. 2022

https://academic.oup.com/narcancer/article/4/2/zcac016/6594019?login=true

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

Attard G, et al. Lancet. 2022

https://www.sciencedirect.com/science/article/pii/S0140673621024375?via%3Dihub

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Jayaram A, et al. Ann Oncol. 2021

https://www.annalsofoncology.org/article/S0923-7534(21)01074-7/fulltext

 

Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.

Conteduca V, et al. JCO Precision Oncology. 2020

https://ascopubs.org/doi/10.1200/PO.18.00302

 

Genome-wide plasma DNA methylation features of metastatic prostate cancer.

Wu A, et al. The Journal of Clinical Investigation. 2020

https://www.jci.org/articles/view/130887

Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis.

Jayaram A, et al. JCO Precision Oncology. 2019

https://ascopubs.org/doi/full/10.1200/PO.19.00123

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.

Conteduca V, et al. Ann Oncol. 2017

https://academic.oup.com/annonc/article/28/7/1508/3792654

Plasma AR and abiraterone-resistant prostate cancer.

Romanel A, et al. Sci Transl Med. 2015

http://stm.sciencemag.org/content/7/312/312re10.full

Tumor clone dynamics in lethal prostate cancer.

Carreira S, et al. Sci Transl Med. 2014

http://stm.sciencemag.org/content/6/254/254ra125.full

Selected publications

bottom of page